8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose Vials, packaged ...
FDA Drug Recall #D-0079-2023 — Class I — November 28, 2022
Recall Summary
| Recall Number | D-0079-2023 |
| Classification | Class I — Serious risk |
| Date Initiated | November 28, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Exela Pharma Sciences LLC |
| Location | Lenoir, NC |
| Product Type | Drugs |
| Quantity | 489,600 vials |
Product Description
8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose Vials, packaged in cartons of 20 vials, Rx only, Manufactured and Distributed by: Exela Pharma Sciences, LLC Lenoir, NC 28645. Carton NDC 51754-5001-5, vial NDC 51754-5001-1.
Reason for Recall
Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.
Distribution Pattern
Nationwide within the United States
Lot / Code Information
Lots: P0001178 Exp. 05/2023; P0001298, P0001301, P0001313, P0001314, P0001317 Exp. 08/2023; P0001330, P0001464 Exp. 09/2023; P0001442 Exp. 11/2023; P0001467, P0001472, P0001486, P0001532 Exp. 12/2023.
Other Recalls from Exela Pharma Sciences LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0620-2025 | Class II | 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/1... | Jul 30, 2025 |
| D-0303-2025 | Class II | 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/... | Mar 7, 2025 |
| D-0118-2024 | Class I | ELCYS (cysteine hydrochloride injection), USP, ... | Oct 18, 2023 |
| D-0116-2024 | Class I | 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/... | Oct 18, 2023 |
| D-0117-2024 | Class I | Midazolam in 0.8% Sodium Chloride Injection 100... | Oct 18, 2023 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.